Latest News & Updates
Other trending news you may like to read
Regeneron’s Dupixent Receives European Commission Approval After Strong Phase 3 Trial Results As First-Line Targeted Therapy For Chronic Spontaneous Urticaria
EU approves Dupixent as first-line targeted therapy for chronic spontaneous urticaria, offering significant itch and hive reduction for patients 12+.
Vaibhavi M.
Novo Nordisk Reports; Amycretin Demonstrates Significant Glycemic Control And Weight Loss In Phase 2 Trial, Paving The Way For Phase 3 Development
Novo Nordisk’s amycretin shows strong Phase 2 results, delivering notable HbA1c reductions and weight loss in adults with type 2 diabetes.
Vaibhavi M.
Eisai Completes FDA Submission For LEQEMBI Weekly Autoinjector, Paving The Way For At-Home Alzheimer’s Treatment
Eisai completes FDA sBLA submission for LEQEMBI IQLIK, a weekly subcutaneous autoinjector offering a home-based option for early Alzheimer’s treatment.
Vaibhavi M.
AstraZeneca’s Imfinzi Regimen Shows Strong EFS And OS Benefits In FDA-Backed MATTERHORN Trial
FDA approves Imfinzi plus FLOT as a new perioperative standard for early gastric and GEJ cancers, improving survival outcomes.
Vaibhavi M.
